keyword
MENU ▼
Read by QxMD icon Read
search

metformin non-glycemic

keyword
https://www.readbyqxmd.com/read/30159178/dapagliflozin-associated-euglycemic-diabetic-ketoacidosis-in-a-patient-presenting-with-acute-pancreatitis
#1
Karun Badwal, Tooba Tariq, Diane Peirce
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a class of medications used for glycemic control in type II diabetes mellitus. Their mechanism of action involves preventing resorption of glucose at the proximal kidney, thereby promoting glucosuria and weight loss. However, they have also been found to be associated with euglycemic diabetic ketoacidosis (euDKA). This case describes a 25-year-old male with a history of type II diabetes on metformin, sitagliptin, and dapagliflozin who was admitted with his third episode of pancreatitis secondary to hypertriglyceridemia...
2018: Case Reports in Endocrinology
https://www.readbyqxmd.com/read/30129089/efficacy-and-safety-of-once-weekly-dulaglutide-versus-insulin-glargine-in-mainly-asian-patients-with-type-2-diabetes-mellitus-on-metformin-and-or-a-sulfonylurea-a-52-week-open-label-randomized-phase-3-trial
#2
Weiqing Wang, Luis Nevarez Ruiz, Ekaterina Filippova, Ki Ho Song, Bei Tao, Liqun Gu, Feng Wang, Pengfei Li, Jun Yang
AIM: We compared the efficacy and safety of once-weekly dulaglutide with insulin glargine in combination with metformin and/or a sulfonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: In this 52-week, randomized, parallel-arm, open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months, hemoglobin (Hb)A1c ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%). The primary outcome was change in HbA1c from baseline to week 26 to determine non-inferiority of dulaglutide 1...
August 21, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/30120754/persistence-to-treatment-with-novel-antidiabetic-drugs-dipeptidyl-peptidase-4-inhibitors-sodium-glucose-co-transporter-2-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-in-people-with-type-2-diabetes-a-nationwide-cohort-study
#3
György Jermendy, Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, István Wittmann, Péter Kempler
INTRODUCTION: Adequate persistence to antidiabetic treatment is highly important to achieve proper glycemic control. In this study we evaluate the persistence to treatment with dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists in a nationwide cohort of patients with type 2 diabetes. METHODS: Using a central database in Hungary, we analyzed the persistence to the treatment with dipeptidyl peptidase-4 inhibitors (n = 59,900), sodium-glucose co-transporter-2 inhibitors (n = 26,052), and glucagon-like peptide-1 receptor agonists (n = 17,332) at treatment intensification between 2014 and 2016...
August 17, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/30072404/sex-and-bmi-alter-the-benefits-and-risks-of-sulfonylureas-and-thiazolidinediones-in-type-2-diabetes-a-framework-for-evaluating-stratification-using-routine-clinical-and-individual-trial-data
#4
John M Dennis, William E Henley, Michael N Weedon, Mike Lonergan, Lauren R Rodgers, Angus G Jones, William T Hamilton, Naveed Sattar, Salim Janmohamed, Rury R Holman, Ewan R Pearson, Beverley M Shields, Andrew T Hattersley
OBJECTIVE: The choice of therapy for type 2 diabetes after metformin is guided by overall estimates of glycemic response and side effects seen in large cohorts. A stratified approach to therapy would aim to improve on this by identifying subgroups of patients whose glycemic response or risk of side effects differs markedly. We assessed whether simple clinical characteristics could identify patients with differing glycemic response and side effects with sulfonylureas and thiazolidinediones...
September 2018: Diabetes Care
https://www.readbyqxmd.com/read/30019498/a-randomized-clinical-trial-of-the-efficacy-and-safety-of-sitagliptin-compared-with-dapagliflozin-in-patients-with-type-2-diabetes-mellitus-and-mild-renal-insufficiency-the-composit-r-study
#5
Russell Scott, Jerry Morgan, Zachary Zimmer, Raymond L H Lam, Edward A O'Neill, Keith D Kaufman, Samuel S Engel, Annaswamy Raji
AIM: To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. MATERIALS AND METHODS: Patients with HbA1c ≥7.0 to ≤9.5% (≥53 to ≤80 mmol/mol) and estimated glomerular filtration rate ≥60 to <90 mL/min/1.73m2 on metformin (≥1500 mg/d) ± sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks...
July 18, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29991320/non-insulin-pharmacological-therapies-for-treating-type-1-diabetes
#6
REVIEW
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst
Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of interest as adjunct therapies to insulin. Areas covered: In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D...
June 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29781752/streptozotocin-induced-diabetes-in-rats-effects-of-white-butterfly-clerodendrum-volubile-leaves-on-blood-glucose-levels-lipid-profile-and-antioxidant-status
#7
Olorunfemi Raphael Molehin, Omotade Ibidun Oloyede, Stephen Adeniyi Adefegha
White Butterfly (Clerodendrum volubile) leaf is commonly used in traditional medicine for the management of various diseases including diabetes without the full understanding of the scientific basis for its use. This study sought to evaluate the antihyperglycemic, antihyperlipidemic and antioxidant effect of C. volubile leaves in streptozotocin (STZ)-induced diabetic rats. Aqueous extract of C. volubile was prepared and its effect assessed on relevant enzymes associated with diabetes. Fifty male Wistar rats were randomly separated into 10 groups each containing five rats...
October 2018: Toxicology Mechanisms and Methods
https://www.readbyqxmd.com/read/29777519/combination-glucose-lowering-therapy-plans-in-t2dm-case-based-considerations
#8
REVIEW
Lawrence Blonde, Susana Dipp, Daniel Cadena
Type 2 diabetes mellitus (T2DM) is a complex disease, and while lifestyle interventions remain the cornerstone of therapy, most patients will also require pharmacotherapy. Current diabetes treatment guidelines and algorithms recommend an individualized approach to setting glycemic goals and selecting treatment. Although a single antihyperglycemic agent may be appropriate as the initial T2DM pharmacotherapy, the progressive nature of the disease due to declining pancreatic β-cell function will result in the vast majority of T2DM patients eventually requiring two or more antihyperglycemic agents...
July 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29761619/changes-in-diabetes-medication-regimens-and-glycemic-control-in-adolescents-and-young-adults-with-youth-onset-type-2-diabetes-the-search-for-diabetes-in-youth-study
#9
Cathy A Pinto, Jeanette M Stafford, Tongtong Wang, R Ravi Shankar, Jean M Lawrence, Grace Kim, Catherine Pihoker, Ralph B D'Agostino, Dana Dabelea
OBJECTIVE: The aim of this study was to describe recent medication patterns and changes in medication patterns and glycemic control in adolescents and young adults with incident type 2 diabetes (T2D). METHODS: Using data from the SEARCH for Diabetes in Youth Study, we conducted a cross-sectional analysis of treatments for adolescents and young adults with incident T2D in 2 periods (2002-2005 vs 2008/2012), and a longitudinal analysis of medications and glycemic control for a subset with baseline and follow-up visits...
May 15, 2018: Pediatric Diabetes
https://www.readbyqxmd.com/read/29744272/antidiabetic-activity-of-mefloquine-via-glp-1-receptor-modulation-against-stz-na-induced-diabetes-in-albino-wistar-rats
#10
Rajnish Kumar Yadav, Jitendra K Rawat, Swetlana Gautam, Manjari Singh, Manish Kumar, Mohd Nazam Ansari, Subhadeep Roy, Abdulaziz S Saeedan, Gaurav Kaithwas
Mefloquine was retrieved as a glucagon -like peptide-1 receptor agonist and, therefore, evaluated for its antidiabetic potential against non-insulin-dependent diabetes mellitus (NIDDM) in experimental animals. NIDDM was induced by single intraperitoneal injection of streptozotocin and nicotinamide (60 + 110 mg/kg) in albino wistar rats. The experimental animals were scrutinised for electrocardiographic (ECG) and heart rate variability (HRV) factors to study the autonomic dysfunction along with blood glucose, serum insulin, and liver glycogen levels for glycemic control...
May 2018: 3 Biotech
https://www.readbyqxmd.com/read/29690976/berardinelli-seip-congenital-generalised-lipodystrophy
#11
Huma Arshad Cheema, Hassan Suleman Malik, Nadia Waheed, Iqra Mushtaq, Zafar Fayyaz, Mohammad Nadeem Anjum
Berardinelli-Seip congenital lipodystrophy (BSCL) syndrome is a rare genetic disorder caused by dysregulation of glycemic and lipid metabolism. We report five BSCL cases with typical clinical pictures and complications. These, to the best of our knowledge, represent the first case series from Pakistan. BSCL is characterized by marked atrophy of adipose tissue, acromegaly, acanthosis nigricans and tall stature. We could not perform genetics studies in any patient owing to non-availability of genetic laboratory in Pakistan...
May 2018: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29417495/effectiveness-and-safety-of-a-novel-care-model-for-the-management-of-type-2-diabetes-at-1-year-an-open-label-non-randomized-controlled-study
#12
Sarah J Hallberg, Amy L McKenzie, Paul T Williams, Nasir H Bhanpuri, Anne L Peters, Wayne W Campbell, Tamara L Hazbun, Brittanie M Volk, James P McCarter, Stephen D Phinney, Jeff S Volek
INTRODUCTION: Carbohydrate restriction markedly improves glycemic control in patients with type 2 diabetes (T2D) but necessitates prompt medication changes. Therefore, we assessed the effectiveness and safety of a novel care model providing continuous remote care with medication management based on biometric feedback combined with the metabolic approach of nutritional ketosis for T2D management. METHODS: We conducted an open-label, non-randomized, controlled, before-and-after 1-year study of this continuous care intervention (CCI) and usual care (UC)...
April 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29412810/glp-1-receptor-agonists-show-neuroprotective-effects-in-animal-models-of-diabetes
#13
Victor A Gault, Christian Hölscher
Enzyme-resistant receptor agonists of the incretin hormone glucagon-like peptide-1 (GLP-1) have shown positive therapeutic effects in people with type 2 diabetes mellitus (T2DM). T2DM has detrimental effects on brain function and impairment of cognition and memory formation has been described. One of the underlying mechanisms is most likely insulin de-sensitization in the brain, as insulin improves cognitive impairments and enhances learning. Treatment with GLP-1 receptor agonists improves memory formation and impairment of synaptic plasticity observed in animal models of diabetes-obesity...
February 2018: Peptides
https://www.readbyqxmd.com/read/29409112/prognostic-factors-for-resected-non-small-cell-lung-cancer-in-patients-with-type-2-diabetes-mellitus
#14
Woo Sik Yu, Chang Young Lee, Seong Yong Park, Jee Won Suh, Kyoung Shik Narm, Dae Joon Kim, Kyung Young Chung, Jin Gu Lee
BACKGROUND: For diabetic patients with lung cancer, blood glucose levels and medications such as metformin and statins may influence survival. OBJECTIVES: This study aimed to determine prognostic survival factors for diabetic patients with resected non-small cell lung cancer. PATIENTS AND METHODS: Between January 2005 and December 2013, 301 patients with type 2 diabetes mellitus who underwent curative resection for non-small cell lung cancer were identified and reviewed retrospectively...
April 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29142561/feto-maternal-outcomes-and-glycemic-control-in-metformin-versus-insulin-treated-gestational-diabetics
#15
Rabia Arshad, Samia Khanam, Fuad Shaikh, Nasim Karim
Objective: To evaluate and compare feto-maternal outcomes and glycemic control in metformin versus insulin treated gestational diabetics. Methods: The study was conducted in 2010- 2012 as a part of M. Phil at Civil hospital, Lyari General Hospital and Mamji Hospital in Karachi. After written informed consent, 71 GDM diagnosed females with WHO criteria were enrolled. They were divided into two groups. Group-A, 32 females were given oral metformin 500 mg TDS while Group-B, 39 females were given insulin 0...
September 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29067058/effect-of-vitamin-d-supplementation-on-reduction-in-levels-of-hba1-in-patients-recently-diagnosed-with-type-2-diabetes-mellitus-having-asymptomatic-vitamin-d-deficiency
#16
Fawad Ahmad Randhawa, Saqib Mustafa, Dur Muhammad Khan, Shahid Hamid
OBJECTIVE: To study the effect of Vitamin D supplementation on reduction in level of HbA1 in patients recently diagnosed with diabetes mellitus Type II having asymptomatic Vitamin D deficiency. METHODS: This randomized control trial was conducted at East Medical Ward Mayo Hospital Lahore for 6 months from January 01 2016 to June 30, 2016. 114 Patients were included through non probability purposive sampling technique. Informed consent and demographic information was collected...
July 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/28940961/peri-operative-continuation-of-metformin-does-not-improve-glycaemic-control-in-patients-with-type-2-diabetes-a-randomized-controlled-trial
#17
A H Hulst, J A W Polderman, E Ouweneel, A J Pijl, M W Hollmann, J H DeVries, B Preckel, J Hermanides
Historically, metformin was withheld before surgery for fear of metformin-associated lactic acidosis. Currently, however, this risk is deemed to be low and guidelines have moved towards the continuation of metformin. We hypothesized that continuing metformin peri-operatively would lower postoperative serum glucose level without an effect on plasma lactate levels. We performed a single-blind multicentre randomized controlled trial in people with type 2 diabetes mellitus scheduled for non-cardiac surgery and continued (MF+ group) or withheld (MF- group) metformin before surgery...
March 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28761738/results-of-the-safety-run-in-part-of-the-metal-metformin-in-advanced-lung-cancer-study-a-multicentre-open-label-phase-i-ii-study-of-metformin-with-erlotinib-in-second-line-therapy-of-patients-with-stage-iv-non-small-cell-lung-cancer
#18
Floriana Morgillo, Morena Fasano, Carminia Maria Della Corte, Ferdinando Carlo Sasso, Federica Papaccio, Giuseppe Viscardi, Giovanna Esposito, Raimondo Di Liello, Nicola Normanno, Annalisa Capuano, Liberato Berrino, Giovanni Vicidomini, Alfonso Fiorelli, Mario Santini, Fortunato Ciardiello
PURPOSE: Our previous works demonstrated the ability of metformin to revert resistance to gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, the optimal dose of metformin to be used in non-diabetic patients still remains to be defined. The phase I-II trial METformin in Advanced Lung cancer (METAL) was designed to identify the maximum tolerated dose and to evaluate safety and activity of metformin combined with erlotinib in second-line treatment of patients with stage IV NSCLC, whose tumours harbour the WT EGFR gene...
2017: ESMO Open
https://www.readbyqxmd.com/read/28699089/cardiovascular-safety-of-antidiabetic-drugs-in-the-hospital-setting
#19
REVIEW
Stacey A Seggelke, Mark C Lindsay, Ingrid Hazlett, Rebecca Sanagorski, Robert H Eckel, Cecilia C Low Wang
PURPOSE OF REVIEW: Patients with diabetes and/or stress hyperglycemia requires good glycemic control in the hospital setting, often requiring the use of glucose-lowering therapy. Standard-of-care dictates that non-insulin therapy be discontinued, with insulin therapy initiated using a basal-bolus approach. However, insulin is associated with a high risk for hypoglycemia and medical errors. Alternatives to insulin are needed in the inpatient setting, but the cardiovascular (CV) safety of non-insulin therapy is a concern...
August 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28674957/a-review-of-the-long-term-efficacy-tolerability-and-safety-of-exenatide-once-weekly-for-type-2-diabetes
#20
REVIEW
Stefano Genovese, Edoardo Mannucci, Antonio Ceriello
INTRODUCTION: Exenatide once weekly (ExeOW, Bydureon® , Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, is the first agent approved for treatment of type 2 diabetes (T2D) that can be administered on a weekly basis. METHODS: Data concerning treatment of T2D with ExeOW are reviewed with special reference to its long-term efficacy, tolerability, and safety. Relevant literature was identified through the PubMed database from inception to January 2015...
August 2017: Advances in Therapy
keyword
keyword
110085
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"